Search Results - therapeutics+%3e+oncology+%3e+oncology+immunotherapy

42 Results

Sort By:

Methods to Improve Chimeric Antigen Receptor (CAR)-T Cell Efficacy Through Rational Sequence and Structural Modifications (UCLA Case No. 2020-497)

UCLA researchers in the Department of Microbiology, Immunology & Molecular Genetics have developed novel engineering methodologies for CAR molecules that overcome the tonic signaling process that leads to T cell exhaustion and poor therapy efficacy. Background: Immunotherapy has become a highly effective method to combat cancer that enhances a...

Published: 2/14/2025 | Inventor(s): Yvonne Chen

Keywords(s): Cancer Immunotherapy

Category(s): Therapeutics > Oncology > Oncology Immunotherapy

Functional Enrichment and Purification of a Therapeutically Superior Population of Cells (Case No. 2024-024)

Summary: UCLA researchers in the Departments of Bioengineering and Biological Chemistry have developed a method for identifying and enriching therapeutically useful cell sub-populations based on their secretions (SEC-seq). Background: Cell function is defined by a myriad of biomolecules that they secrete; over 3 thousand proteins are estimated to...

Published: 3/3/2025 | Inventor(s): Dino Di Carlo, Kathrin Plath, Shreya Udani, Justin Langerman

Keywords(s): Cell Surface Receptor, Cytometry, Flow Cytometry, Functional Genomics, High-Throughput Screening, hydrogel, Microfluidics, single cell analysis, Therapeutics

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Life Science Research Tools, Life Science Research Tools > Research Methods, Diagnostic Markers > Targets And Assays, Therapeutics > Cell Therapy

Inhibitory Chimeric Antigen Receptors That Reduce Car-T Cell “On-Target, Off-Tumor” Toxicity (UCLA Case No. 2022-186)

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics, and the Department of Molecular and Medical Pharmacology have recently developed a novel approach which improves the kinetics and specificity of CAR T-cell therapy. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered...

Published: 2/14/2025 | Inventor(s): Owen Witte

Keywords(s): blood cancers, CAR-T cell therapy

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics

Inhibition of BMI1 Eliminated Cancer Stem Cells and Activates Antitumor Immunity (UCLA Case No. 2020-858)

UCLA researchers in the Department of Dentistry discovered that targeting BMI1in head and neck squamous cell carcinoma (HNSCC) may be a viable immune checkpoint to inhibit metastatic tumor growth, and prevent tumor relapse through activation of cell-intrinsic immunity and purging cancer stem cells (CSCs). BACKGROUND: Cancer stem cells are cancer...

Published: 2/14/2025 | Inventor(s): Cun Yu Wang, Jia Lingfei

Keywords(s): Cancer stem cells, Epigenetics, Immunooncology, Oncology Immunotherapy, Tumor

Category(s): Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Gene Therapy And Editing

Targeting Prostate Cancer with a Novel T-Cell Receptor and Tissue-Specific Cancer Antigens for Improved Immune Response (UCLA Case No. 2022-070)

Researchers from UCLA’s Department of Microbiology, Immunology, & Molecular Genetics (MIMG), and the department of Molecular and Medical Pharmacology have identified a set of tissue-specific antigens which have been used to isolate and characterize a group of novel T-cell receptors (TCRs) which target prostate cancer specifically. Furthermore,...

Published: 2/14/2025 | Inventor(s): Owen Witte, Zhiyuan Mao, Jami Witte, Pavlo Nesterenko, John Lee

Keywords(s): Cancer, cancer antigen, Peptide, peptides, prostate cancer, protein, t-cells

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

New Fusion Molecule Based on Novel TAA Variant (UCLA Case No. 2007-217)

BACKGROUND: Renal cell carcinoma (RCC) affects approximately 39,000 Americans and causes an estimated 13,000 deaths per year. Metastatic RCC poses a therapeutic challenge because of its resistance to conventional modes of therapy. Approximately one third of RCC patients will present at the metastatic stage and one third of patients with localized disease...

Published: 2/14/2025 | Inventor(s): Arie Belldegrun, Zhenhua Li

Keywords(s): Cancer, Immunotherapy, Renal, Renal cell carcinoma, renal diseases

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Renal

Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)

UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...

Published: 2/14/2025 | Inventor(s): Antoni Ribas

Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor

Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)

Combination of Supercharged NK with Supercharged Gamma Delta T Cells and Supercharged CD8+ T Cells and Super Charged iNKT Cells Should Eliminate Both (UCLA Case No. 2022-322)

SUMMARY: Researchers at UCLA’s School of Dentistry have developed methods and protocols for culturing and priming various immune cells into a “supercharged” phenotype. The studied cell types include NK and iNKT cells, gamma delta T cells, and CD8+ T cells. When deployed in combination, these supercharged cells were found to eliminate...

Published: 2/14/2025 | Inventor(s): Anahid Jewett

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2022-129 Development of Nano-Delivered CXCR4 Antagonist Carrier to Affect Tumor Microenvironment

SUMMARY: UCLA researchers in the David Geffen School of Medicine have developed a nanocarrier platform to deliver drugs that block CXCR4 directly in tumor microenvironments, with an impact on immune cell trafficking and reducing the tumor’s metastatic burden. BACKGROUND: Cancer remains among the leading causes of death worldwide, and its burden...

Published: 2/14/2025 | Inventor(s): Andre Nel

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

2023-043: Enhanced Gamma Delta T Cells for Immunotherapy

SUMMARY: UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have developed a novel platform to generate potent, high quality Vδ2 T cells at scale for use in cancer immunotherapies. BACKGROUND: With rising cases of cancer in the world, immunotherapies have emerged as a promising and potentially effective therapeutic...

Published: 2/14/2025 | Inventor(s): Lili Yang

Keywords(s):

Category(s): Therapeutics, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

1 2 3 4 5